Choosing the Right Path Towards
Meaningful Use

The first stage of Meaningful Use involves data collection, and can earn your practice up to $39,000 per provider.

  • Help your practice receive up to $15,000 per provider in 2013, and up to $39,000 per provider over the next 4 years
  • Learn how to advance your workflow efficiency towards full EHR integration
  • Receive guidance on forthcoming regulatory concerns and compliance

Listen to a Miraca Life Sciences expert walk you through Stage 1 of MU.

The second stage of Meaningful Use is focused on Interoperability and Connectivity.

  • Prepare for your Meaningful Use audit by ensuring adherence to CMS requirements
  • Avoid potential Medicare penalties in 2014 and successfully attest to Meaningful Use requirements
  • Prepare for the revolution in medical billing, ICD10, with guidance from our knowledgeable experts

Listen to a Miraca Life Sciences expert walk you through Stage 2 of MU.

In accordance with the HITECH Act, every applicable healthcare organization must be Meaningful Use compliant by 2015. While the complexities of transitioning to Meaningful Use may seem daunting, we have the capabilities and experience necessary to guide you along the way. EHRpath is our new comprehensive service and support system that forges a long-term partnership with healthcare professionals to decode and take action towards Meaningful Use compliance. From EHR integration to assistance in receiving nearly $40,000 in Meaningful Use incentives, we’re here to help prepare your practice for the future.

EHRpath supports your practice through pathology, technology and Meaningful Use guidance.

EHRpath builds upon our comprehensive knowledge in working with EHRs to give you confidence when integrating a new system. Our wide knowledge base allows us to help you analyze your practice's needs and find a solution that is tailored to your workflow. In addition, we organize and document the entire process to help you get the most out of the government's incentive program. It's a complete consulting solution that not only partners with your practice throughout the EHR integration process, but also provides tailored workflow solutions to help you maximize your system.

Experience You Can Use →
As a leading provider of pathology services, we work with EHR systems on a daily basis. Learn how we can put our experience to work for you.

Meaningful Use Guidance →
From CMS requirements to EHR policies and procedures, discover how EHRpath can help navigate the challenges that come with EHR system integration.

Start on the path towards full EHR integration. Contact us at 855.EHR.PATH (347.7284) or email us at

Choose Miraca for Your Patients

Learn more about Miraca's Anatomic Pathology services

Learn More »

Miraca has been extremely helpful to our office with Meaningful Use. It is such a complex task to undertake, and having knowledgeable people from Miraca to assist with each stage, work flow, and administration is invaluable. You guys have saved us countless hours. Everyone we’ve encountered from Miraca from the beginning like yourself [Rick Ludwico], and now with Joy [Rios], and Amy [Schmid] have been terrific. We count on you guys, and you have guided us throughout the whole process, making it so much easier than it would be otherwise!.
— Pam Kefer, Office Manager
Wallach Derma Center, Danville, Calif.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News

November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading

August 10, 2016

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile […]

Continue reading

July 13, 2016

Miraca Life Sciences Launches Easy Way to Complete GIQuIC Pathology Section

IRVING, Texas, July 13, 2016 — Working with a leading vendor of gastroenterology software, Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, now enables the pathology section of the GIQuIC form to populate automatically. Miraca Life Sciences’ structured diagnosis data and smart electronic interfaces facilitate this easier process, which improves the current approach of using free-form text for […]

Continue reading

Miraca Life Sciences Adds New Way to Complete GIQuIC Pathology Section and Automate ADR Tracking

IRVING, Texas, July 13, 2016 — Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, has worked closely with Wolters Kluwer throughout its latest software release of ProVation® MD to automatically populate the pathology section of the GIQuIC form for single colonoscopies, which will save hours of time for clients. Miraca Life Sciences’ use of structured diagnostic terminology combined […]

Continue reading

June 16, 2016

Miraca Life Sciences Launches InformTx™ Therapeutic Drug Monitoring for Four Biologic Drugs, Including Firsts for the United States

IRVING, Texas, June 16, 2016 — Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, has expanded into clinical pathology testing with its launch of InformTx therapeutic drug monitoring (TDM) for patients with inflammatory bowel disease (IBD). The InformTx assays measure both drug and anti-drug antibody levels for infliximab (trade name Remicade®), adalimumab (trade name Humira®), certolizumab (trade name […]

Continue reading